Stereopsis after Intravitreal Ranibizumab Injections for Branch Retinal Vein Occlusion.


Journal

Ophthalmology. Retina
ISSN: 2468-6530
Titre abrégé: Ophthalmol Retina
Pays: United States
ID NLM: 101695048

Informations de publication

Date de publication:
09 2019
Historique:
received: 01 01 2019
revised: 01 04 2019
accepted: 01 04 2019
pubmed: 4 6 2019
medline: 22 8 2020
entrez: 4 6 2019
Statut: ppublish

Résumé

To evaluate stereopsis before and after intravitreal ranibizumab (IVR) injections in patients with branch retinal vein occlusion (BRVO) and investigate the relationship between stereopsis and retinal microstructure. Prospective, observational, controlled study. Thirty-two eyes of 32 patients undergoing IVR treatment for BRVO and 28 eyes of age-matched healthy control participants. Stereopsis was measured using the Titmus stereo test (TST) and TNO stereo test before and 1, 2, 3, 4, 5, and 6 months after treatment. Stereopsis, best-corrected visual acuity (BCVA), duration of disease, central retinal thickness, status of the external limiting membrane, ellipsoid zone, and external limiting membrane, and serous retinal detachment (SRD) after treatment. Treatment with IVR significantly improved the TST (P < 0.001) and TNO stereo test (P < 0.05) scores as well as BCVA (P < 0.001) and central retinal thickness (P < 0.005). Stereopsis after IVR injection in eyes with BRVO was significantly worse than that in healthy control participants (TST, P < 0.001; TNO stereo test, P < 0.001). The TST and TNO stereo test scores were correlated significantly with BCVA and the presence of SRD at baseline. After 6 months of treatment, an association of TST and TNO stereo test scores with BCVA and status of the external limiting membrane and ellipsoid zone was observed. Stereopsis after treatment showed a significant relationship with BCVA and presence of SRD at baseline. Administration of IVR for BRVO improved early stereopsis, albeit not to a normal level. Presence of SRD and visual acuity were predictors of stereopsis after treatment in patients with BRVO.

Identifiants

pubmed: 31155472
pii: S2468-6530(19)30023-5
doi: 10.1016/j.oret.2019.04.003
pii:
doi:

Substances chimiques

Angiogenesis Inhibitors 0
VEGFA protein, human 0
Vascular Endothelial Growth Factor A 0
Ranibizumab ZL1R02VT79

Types de publication

Controlled Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

777-783

Informations de copyright

Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Auteurs

Shohei Morikawa (S)

Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Fumiki Okamoto (F)

Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. Electronic address: fumiki-o@md.tsukuba.ac.jp.

Yoshimi Sugiura (Y)

Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Tomoya Murakami (T)

Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Takahiro Hiraoka (T)

Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Tetsuro Oshika (T)

Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH